Pulse Biosciences, Inc. (FRA:6L8)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.35B +262.6% |
| Revenue (ttm) | 1.04M |
| Net Income | -70.07M |
| EPS | -1.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 43.80 |
| Previous Close | 42.80 |
| Day's Range | 43.80 - 46.00 |
| 52-Week Range | 10.80 - 48.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso... [Read more]
News
Pulse Biosciences falls -10.6%
Pulse Biosciences (PLSE) is down -10.6%, or -$5.85 to $49.35.
Pulse Biosciences falls -6.2%
Pulse Biosciences (PLSE) is down -6.2%, or -$3.42 to $51.78.
Pulse Biosciences announces two milestones in PRECISE-BTN study
Pulse Biosciences (PLSE) announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules...
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences rises 19.5%
Pulse Biosciences (PLSE) is up 19.5%, or $9.53 to $58.32.
Pulse Biosciences initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $73 price target The firm says the atrial fibrillation ablation market is large, growing and “disruptable.” Pulse’s...
Pulse Biosciences announces inducement grants under Nasdaq listing rule
Pulse Biosciences (PLSE) announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company’s 2017…
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Pulse Biosciences announces inducement grants under Nasdaq listing rule
Pulse Biosciences (PLSE) announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company’s 2017…
Pulse Biosciences initiated with a Buy at Needham
Needham initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $58 price target The company has developed “differentiated” pulse field ablation platform technology, Nanosecond Pulsed Fie...
Pulse Biosciences management to meet virtually with BTIG
Virtual Meeting to be held on August 14 hosted by BTIG.
Pulse Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
Leadership with deep med tech and VC experience is driving rapid progress in next-generation nsPFA technology, which shows unprecedented efficacy and efficiency in AFib treatment. Strong clinical data, a unique competitive position, and a partnership-focused strategy support broad future applications.
Pulse Biosciences management to meet virtually with BTIG
Virtual Meeting to be held on August 17-18 hosted by BTIG.
Pulse Biosciences price target raised to $43 from $32 at Canaccord
Canaccord raised the firm’s price target on Pulse Biosciences (PLSE) to $43 from $32 and keeps a Buy rating on the shares. The firm said Pulse continues to make clinical-regulatory…
Pulse Biosciences price target raised to $45 from $30 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Pulse Biosciences (PLSE) to $45 from $30 and keeps an Outperform rating on the shares. The firm sees improving success…
Pulse Biosciences Slides: Investor presentation
Pulse Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Pulse Biosciences reports Q2 EPS (36c) vs (28c) last year
Reports Q2 revenue $400,000, consensus $533,330. “This was a highly productive quarter for Pulse Biosciences (PLSE), defined by exceptional momentum in our cardiac catheter program,” said Paul LaViole...
Pulse Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 saw rapid clinical trial enrollment, strong physician enthusiasm, and expanded partnerships, with revenue of $434,000 and a strengthened cash position of $101.6 million. Key IDE studies are ahead of schedule, and capital raised supports continued clinical and market development.
Pulse Biosciences Earnings release: Q2 2026
Pulse Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Pulse Biosciences Quarterly report: Q2 2026
Pulse Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Pulse Biosciences management to meet with BTIG
Medical Technology & Digital Health Analyst Thibault holds a virtual meeting with management on August 10 hosted by BTIG.
Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF study
Pulse Biosciences (PLSE) announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026. “We are very pleased by the strong enrollment trajectory ...
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...